| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:26-29.)
© 2004 American Heart Association, Inc.
Brief Rapid Communications |
From the Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn.
Correspondence to Dan M. Roden, MD, Professor of Medicine and Pharmacology, Director, Division of Clinical Pharmacology, 532 Robinson Research Building, Vanderbilt University School of Medicine, Nashville, TN 37232. E-mail dan.roden{at}vanderbilt.edu
Received October 8, 2003; revision received November 4, 2003; accepted November 14, 2003.
Background Cases of QT prolongation, torsades de pointes, and sudden death have been reported with arsenic trioxide (As2O3), a highly effective agent for acute promyelocytic leukemia. In this study, we evaluated the effects of As2O3 on repolarizing cardiac ion currents.
Methods and Results In HERG- or KCNQ1+KCNE1-transfected CHO cells (n=32; total), As2O3 caused concentration-dependent block of both IKr and IKs, with an IC50 for tail current block of 0.14±0.01 µmol/L for IKr and 1.13±0.06 µmol/L for IKs. In contrast to other QT-prolonging drugs, As2O3 also activated a time-independent current that additional experiments identified as IK-ATP.
Conclusions As2O3 blocks both IKr and IKs at clinically relevant concentrations. On the other hand, it also activates IK-ATP, which maintains normal repolarization. We infer that variability in the extent of QT interval prolongation and onset of ventricular arrhythmias during arsenic therapy represents competing effects to block and activate multiple repolarizing potassium currents.
Key Words: torsades de pointes drugs ion channels
This article has been cited by other articles:
![]() |
S. M. Schumacher, D. P. McEwen, L. Zhang, K. L. Arendt, K. M. Van Genderen, and J. R. Martens Antiarrhythmic Drug-Induced Internalization of the Atrial-Specific K+ Channel Kv1.5 Circ. Res., June 19, 2009; 104(12): 1390 - 1398. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-W. Siu, W.-Y. Au, C. Yung, C. R. Kumana, C.-P. Lau, Y.-L. Kwong, and H.-F. Tse Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety Blood, July 1, 2006; 108(1): 103 - 106. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Katchman, J. Koerner, T. Tosaka, R. L. Woosley, and S. N. Ebert Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1098 - 1106. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Mari, E. Bertol, V. Fineschi, and S. B Karch Channelling the Emperor: what really killed Napoleon? J R Soc Med, August 1, 2004; 97(8): 397 - 399. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ficker, Y. A. Kuryshev, A. T. Dennis, C. Obejero-Paz, L. Wang, P. Hawryluk, B. A. Wible, and A. M. Brown Mechanisms of Arsenic-Induced Prolongation of Cardiac Repolarization Mol. Pharmacol., July 1, 2004; 66(1): 33 - 44. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |